"10.1371_journal.pone.0104530","plos one","2014-08-11T00:00:00Z","Yaakov A Levine; Frieda A Koopman; Michael Faltys; April Caravaca; Alison Bendele; Ralph Zitnik; Margriet J Vervoordeldonk; Paul Peter Tak","SetPoint Medical Corporation, Valencia, California, United States of America; Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands; Bolder BioPATH, Inc., Boulder, Colorado, United States of America; Arthrogen BV, Amsterdam, the Netherlands; GlaxoSmithKline, Stevenage, United Kingdom; University of Cambridge, Cambridge, United Kingdom","Conceived and designed the experiments: YAL MF AB RZ PPT. Performed the experiments: YAL FAK AC AB. Analyzed the data: YAL FAK AB RZ MJV PPT. Contributed reagents/materials/analysis tools: YAL FAK AB RZ MJV PPT. Wrote the paper: YAL FAK RZ MJV PPT. Designed and developed the external pulse generator and software environment: MF.","YAL, MF, AC and RZ are employees of SetPoint Medical Corporation. PPT is a consultant to and has received research grants from SetPoint Medical. PPT has become an employee of GlaxoSmithKline (GSK) after completion of the study. GSK has obtained an equity interest in Setpoint Medical Corporation. FAK, AB, and MJV have no competing interests to declare. This does not alter the authors adherence to all PLOS ONE policies on sharing data and materials.","2014","08","Yaakov A Levine","YAL",8,FALSE,5,4,6,5,TRUE,TRUE,FALSE,0,NA,FALSE
